Curis reports Q1 EPS (12c) , consensus (12c)

Reports Q1 revenue $2.2M, consensus $2.47M. Curis expects its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2025. “We are very pleased with our progress this quarter, as we were able to work with the FDA to remove the partial clinical hold on the TakeAim Leukemia study a quarter ahead of schedule. In that process, we also gained alignment with FDA in confirming 300 mg BID as the RP2D for monotherapy, which we believe is the optimal monotherapy dose. We appreciate the strong support of our clinical investigators during our discussions with FDA and we are excited to expand patient enrollment in the TakeAim Leukemia study at the RP2D,” said James Dentzer, CEO.